Bessemer Group
ARQT icon

Bessemer Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Bessemer Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Buy
190
+52
+38% +$1.33K ﹤0.01% 2249
2025
Q4 		$4K Hold
138
– – ﹤0.01% 2276
2025
Q3 		$3K Buy
+138
New +$2.18K ﹤0.01% 2219
2024
Q4 		– Sell
-110
Closed -$1K – 2456
2024
Q3 		$1K Sell
110
-250
-69% -$2.47K ﹤0.01% 2327
2024
Q2 		$3K Buy
+360
New +$3.26K ﹤0.01% 1808

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bessemer Group's ARQT Position: Q1 2026 in Review

Bessemer Group increased its Arcutis Biotherapeutics (ARQT) stake by 38% in Q1 2026, buying an estimated $1.33K and bringing the position to 190 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Bessemer Group first reported a position in ARQT in Q2 2024 and has held it in 5 quarters since. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Bessemer Group held 190 shares of Arcutis Biotherapeutics worth $4K as of Q1 2026.
  • Bessemer Group bought 52 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.33K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2249 holding.
  • Bessemer Group first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 5 quarters since.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.